Comparison of Two PPOS Models for Pituitary Suppression
The scarcity of evidence regarding the interchangeable use of different progestogens poses challenges, particularly in international egg donation and fertility preservation programs where standardizing protocols is crucial for achieving consistent efficacy, efficiency, and safety outcomes. Consequently, there's a pressing need for clinical studies to assess the effects of various progestogens on clinical outcomes in controlled ovarian hyperstimulation cycles. This study, a pioneering effort, aims to compare the effects of two progestogens on oocyte performance, safety, and efficiency in an egg donation program involving young, healthy, normo-responding patients.
- EligibilityCriteria: Inclusion Criteria:  BMI of 18-29,9 kg/m2 Ultrasound count of antral follicles prior to COH ≥ 12 follicles Meeting the criteria for inclusion in the egg donation program Normal karyotype and no active sexually transmitted diseases No use of combined hormonal contraceptives one month before COH  Exclusion Criteria:  Patients excluded from the egg donation program Untreated sexually transmitted diseases, positive serology for HBV, HIV, HCV Blood disorders, neurodegenerative/psychiatric diseases, carriers of X-linked genetic diseases, oncological diseases, endometriosis. Oligomenorrhea (<1 menstrual cycle in 3 months) Use of combined hormonal contraceptives before COH - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - MaximumAge: 34 Years - StdAgeList: Adult